Sotrovimab reduces the likelihood of hospitalization in at-risk outpatients with mild to moderate COVID-19 (NNT = 16)
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2024 Unbound Medicine, Inc. All rights reserved